Full-Time

Territory Sales Manager

Confirmed live in the last 24 hours

Calyxo

Calyxo

51-200 employees

Develops medical devices for kidney stone treatment

Compensation Overview

$120k/yr

+ Variable Compensation + Stock Options

Senior

No H1B Sponsorship

Sacramento, CA, USA

Candidates must live in or around the Sacramento Area.

Category
Field Sales
Sales & Account Management
Requirements
  • Bachelor’s degree or equivalent experience
  • 5+ years of outside sales/sales management experience
  • Strong track record of over-delivering revenue versus sales plan
  • Proficient in navigating and accelerating hospital and ASC product approval processes
  • Operating room experience required
  • Thorough knowledge of urology and urology products and strong relationships with local urologists highly desired
  • Successful track record of launching new and disruptive technologies and well-versed and proficient in complex reimbursement environments
  • Compliance with relevant vaccination county, state, and federal rules
Responsibilities
  • Meet or exceed quarterly sales quota for the defined area.
  • Maintain a monthly and quarterly territory plan that outline territory sales objectives and areas of vulnerability.
  • Provide monthly forecasts for defined area.
  • Effectively communicate the value proposition of Calyxo products to customers.
  • Qualify, train, assess, and develop accounts to adopt Calyxo products as an integral part of their kidney stone practice with the goal of demonstrating high account adoption.
  • Communicate current market conditions and recommend improvements to the commercial process.
  • Partner with Professional Education to deliver outstanding clinical and training support to ensure physicians quickly become clinically independent.
  • Build and maintain relationships with key customers and KOLs within defined region.
  • Partner closely with the Regional Sales Manager, Sales team, and Marketing team to identify and prioritize customers for higher-level corporate relationships.
  • Partner with the Customer Service team to meet and exceed customer expectations.
  • Partner with the Regional Sales Manager and Finance team to ensure all required sales reporting forms are completed and submitted on time.
  • Provide support for the resolution of product complaints and/or safety issues.
  • Proactively support organizational goals and objectives, policies and procedures, Good Manufacturing Practices, and FDA regulations, including strict compliance with Calyxo’s Customer Relationship and the Sunshine Act policies.
  • Maintain a professional and credible image with key physicians, consultants, suppliers, and teammates.
  • Establish and maintain credentials (via RepTrax, Vendormate, etc) to enter and work in hospitals and other medical facilities as required by facility requirements.
  • Manage travel and expenses per approved budget.
  • Perform other duties as assigned.
  • Contribute to our culture of being collaborative, respectful, transparent, ethical, efficient, high-achieving, and fun!
Desired Qualifications
  • Medical device experience preferred
  • Understanding of the treatment algorithm for patients with kidney stones preferred

Calyxo develops medical devices specifically designed to treat kidney stones. Their products focus on improving the effectiveness and safety of treatment options available to urologists. By collaborating with leading urologists, Calyxo ensures that their devices meet the real clinical needs of healthcare providers. Unlike many competitors, Calyxo emphasizes a strong partnership with medical professionals to enhance patient care and clinical outcomes. The company's goal is to provide advanced solutions that enable urologists to treat kidney stones more efficiently, ultimately improving the overall experience for patients.

Company Size

51-200

Company Stage

Series D

Total Funding

$97.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance for the redesigned CVAC System boosts market credibility and adoption.
  • Rising prevalence of kidney stones expands Calyxo's potential customer base.
  • Series D funding of $50M supports further innovation and market expansion.

What critics are saying

  • Emerging competition may impact Calyxo's market share in kidney stone treatments.
  • Economic downturns could reduce healthcare spending on new medical devices.
  • Rapid technological advancements require Calyxo to continuously innovate to stay competitive.

What makes Calyxo unique

  • Calyxo's CVAC System offers superior stone clearance compared to standard URS.
  • The company focuses on minimally invasive kidney stone treatments with high patient satisfaction.
  • Calyxo collaborates with leading urologists to enhance R&D and device innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-7%
Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

Finsmes
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

Business Wire
Jul 6th, 2022
Calyxo Raises $32.7 Million In Series C Financing To Support Novel Approach To Treating Kidney Stones

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG. Calyxo has developed the innovative CVAC Aspiration System that utilizes irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome, a challenge that has always been difficult to achieve consistently